EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ribitoborate Synergism with Histone Deacetylase Inhibitor Romidepsin as a Potential Treatment for Breast Cancer

Ravi Doddapaneni, Jason D Tucker iD, Jian Zhang iD, Pei J Lu, Qi L Lu

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27188033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ravi Doddapaneni und 4 weiteren Autor:innen. Beteiligte Einrichtung: McColl-Lockwood Laboratory for Muscular Dystrophy Research, Atrium Health Musculoskeletal Institute, Carolinas Medical Center, Wake Forest University…. Hauptthemen laut MEDLINE: Depsipeptides, Histone Deacetylase Inhibitors, Triple Negative Breast Neoplasms. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Atrium Health Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is a subtype associated with poor prognosis and low survival rates, largely due to limited treatment options. In recent years, histone deacetylase (HDAC) inhibitors have emerged as promising anti-cancer candidates due to their attractive epigenetic properties and distinct mechanisms of action but have shown limited success in solid tumors. Here, we explore ribitoborate along with HDAC inhibitors for potential use as a treatment for TNBC. Experiments were performed on the TNBC cell line MDA-MB-231. The results of the study revealed that ribitoborate and romidepsin showed synergistic responses leading to significant arrest of cell proliferation (80%) (p < 0.01) as well as migration inhibition. These effects were associated with downregulation of c-Myc, survivin, Bcl-2, and cyclin D1, as well as upregulation of p53 and p21 proteins; notably the changes were significantly greater with the combined treatment than with either ribitoborate or romidepsin alone. Romidepsin and ribitoborate combined treatment time-dependently increased cell death of MDA-MB-231 cells with greater efficiency than romidepsin alone. Cell death by apoptosis was supported by the upregulation of H3k9 and H3k27 acetylation with decreasing proliferation. These results suggest the great potential of the drug combination for treatment of TNBC. The underlying molecular mechanisms for synergy could be further explored for potential development of new combined therapy for breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DepsipeptidesHistone Deacetylase InhibitorsTriple Negative Breast NeoplasmsHumansFemaleMDA-MB-231 CellsCell ProliferationDrug SynergismApoptosisCell Line, TumorCell MovementGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

histone deacetylase inhibitorsribitoborateromidepsintriple-negative breast cancer

Substanzen

DepsipeptidesromidepsinHistone Deacetylase Inhibitors

Autor:innen und Institutionen

  • McColl-Lockwood Laboratory for Muscular Dystrophy Research, Atrium Health Musculoskeletal Institute, Carolinas Medical Center, Wake Forest University School of Medicine, Charlotte, NC 28203, USA.
  • Fitzsimons Bioscience Park Center, Z Biotech, LLC, Aurora, CO 80045, USA.

ORCID-Profile: Jason D Tucker, Jian Zhang

Förderung

  • Atrium Health Foundation

Zitieren

APA

Doddapaneni, R., Tucker, J. D., Zhang, J., Lu, P. J., & Lu, Q. L. (2026). Ribitoborate Synergism with Histone Deacetylase Inhibitor Romidepsin as a Potential Treatment for Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188033

Vancouver

Doddapaneni R, Tucker JD, Zhang J, Lu PJ, Lu QL. Ribitoborate Synergism with Histone Deacetylase Inhibitor Romidepsin as a Potential Treatment for Breast Cancer. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188033

BibTeX
@article{Doddapaneni2026,
  author = {Doddapaneni, Ravi and Tucker, Jason D and Zhang, Jian and Lu, Pei J and Lu, Qi L},
  title = {Ribitoborate Synergism with Histone Deacetylase Inhibitor Romidepsin as a Potential Treatment for Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27188033}
}
Kostenlos starten →